Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jared Andre

Internal Medicine Chicago, IL Medical Doctor

NPI 1528470291 CMS profile 4833604

2535 S Martin Luther King Drive, Chicago, IL 60616

Open in the dashboard

General payments

$10,939

504 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jared Andre of Chicago, IL is reported in the CMS Open Payments database as having received $10,939 across 504 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,125 136
2024 General $3,556 154
2023 General $2,123 98
2022 General $1,156 58
2021 General $655 36
2020 General $31 2
2019 General $293 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Andre
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jared Andre were reported at $3,125. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jared Andre Internal Medicine median Middle half National median
2019 $293 $159 $48–$570 $163
2020 $31 $119 $33–$402 $114
2021 $655 $135 $37–$521 $132
2022 $1,156 $141 $42–$496 $149
2023 $2,123 $149 $45–$519 $160
2024 $3,556 $154 $47–$537 $164
2025 $3,125 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,759 135 payments
  2. AstraZeneca Pharmaceuticals LP $1,783 68 payments
  3. Lilly USA, LLC $1,315 62 payments
  4. Pfizer Inc. $1,175 54 payments
  5. Novo Nordisk Inc $996 53 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $526 23 payments
  7. Novartis Pharmaceuticals Corporation $480 24 payments
  8. Exact Sciences Corporation $277 12 payments
  9. Merck Sharp & Dohme Corporation $234 10 payments
  10. Otsuka America Pharmaceutical, Inc. $233 13 payments
  11. Other $1,160 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,939 504 payments
Products named General payments · program years 2019–2025
  1. LINZESS $1,015 39 payments
  2. UBRELVY $988 56 payments
  3. AIRSUPRA $973 35 payments
  4. JARDIANCE $681 32 payments
  5. CREON $665 26 payments
  6. QULIPTA $629 35 payments
  7. ELIQUIS $579 25 payments
  8. FARXIGA $520 21 payments
  9. Ozempic $493 28 payments
  10. Wegovy $439 20 payments
  11. Other $7,408 344 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 136 drugs

Part D claims

8,167

Median for Internal Medicine: 777

Drug cost

$762,262

Median for Internal Medicine: $73,373

Branded share of claims

19.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 92 $117,921
Mounjaro Tirzepatide Brand 74 $81,183
Ozempic Semaglutide Brand 75 $78,296
Jardiance Empagliflozin Brand 55 $74,527
Trulicity Dulaglutide Brand 47 $73,966
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 54 $53,519
Januvia Sitagliptin Phosphate Brand 34 $32,181
Rybelsus Semaglutide Brand 13 $30,971
Vraylar Cariprazine Hcl Brand 14 $20,888
Linzess Linaclotide Brand 17 $17,535

The 10 drugs with the highest cost, of 136 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$143,530

Of which drugs: $11,058

Medicare patients

325

Average age 74

Services billed

2,544

146 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 42%
Diabetes 25%
Ischemic heart disease 23%
Atrial fibrillation 23%
Chronic kidney disease 18%
Heart failure 16%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 28 28 $8,077
Vaccine for influenza for injection into muscle 90662 Office 36 36 $2,926

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $437
$437 — —
JARDIANCE
  • Lilly USA, LLC $193
  • Boehringer Ingelheim Pharmaceuticals, Inc. $122
$315 55 —
LINZESS
  • AbbVie, Inc. $212
$212 17 —
CREON
  • AbbVie, Inc. $212
$212 — —
ELIQUIS
  • PFIZER INC. $184
$184 92 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

504 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record